Skip to content
Par Drugs & Chemical logo

Par Drugs & Chemical

PAR NSE
₹114.96 5.47 (5.00%)
Market Cap
₹141 Cr
P/E
9.76

Par Drugs & Chemical (PAR) share price was ₹114.96 at the 28 Oct 2026 close; market capitalisation ₹141 Cr; P/E (TTM) 9.76; sector Healthcare. The share price rose 14.0% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 20.1% year on year to ₹31.28 Cr and net profit rose 41.4% year on year to ₹4.71 Cr (compared with Jun 2025). Promoters held 73.41% of Par Drugs & Chemical in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 64/100 (Good) as of 28 Oct 2026.

Close 28 Oct 2026 ₹114.96 +14.15 +14.04% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹141 Cr
P/E (TTM)
9.76
EBITDA
₹21.10 Cr
Return on Equity
11.71%
Debt to Equity
0
Book Value
₹91.01
EPS (TTM)
₹11.78
52W High
₹180.00
52W Low
₹78.05

Price-based figures as of 28 Oct 2026, 15:28 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,757.5034.864,21,683 Cr5.050.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,558.5086.752,53,748 Cr15.140.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,557.0071.541,73,334 Cr9.430.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,181.90107.801,17,891 Cr22.240.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,175.5026.161,17,257 Cr4.330.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,335.4034.591,11,463 Cr2.870.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.6032.721,10,321 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Par Drugs & Chemical (this company)
₹114.969.76141 Cr1.261.14%11.71%15.09%112 Cr14 Cr
Median 8 companies₹1,561.5534.731,17,574 Cr4.690.72%12.98%16.52%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100. How it works →

As of 2026-10-28
v2.0.0
64 Good
Overall score
Data confidence 100/100
surveillance:ESM1

Category scores

Quality Strong 77
Returns, margins, earnings quality 22%
Valuation Strong 82
Cheap vs sector & own history 24%
Growth Weak 43
Sales & profit trajectory 9%
Financial Health Strong 86
Solvency, leverage, coverage 9%
Momentum Strong 85
Trend strength, vol-adjusted 12%
Ownership Average 50
FII/DII/promoter flows 24%

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is almost debt free.
  • Stock is trading at 1.15 times its book value

Weaknesses

3
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 11.3% over past five years.
  • Company has a low return on equity of 13.4% over last 3 years.

Technical Indicators

Oscillators

BearishNeutralBullish

Bearish

Bearish
3
Neutral
5
Bullish
1

Overall

BearishNeutralBullish

Bullish

Bearish
5
Neutral
5
Bullish
9

Moving Averages

BearishNeutralBullish

Bullish

Bearish
2
Neutral
0
Bullish
8

Growth Rate

Revenue Growth
4.46% higher than 3Y

change over 1 year

Net Income Growth
-2.24% lower than 3Y

change over 1 year

Cash Flow Change
1.67%

change over 1 year

EBITDA Margin Change
-6.52%

change over 1 year Operating margin 20.36% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
22.93
25.89
24
22.82
22.61
34.66
21.38
22.33
26.05
28.66
29.34
19.61
31.28
Expenses
18.79
18.53
18.77
16.72
18.37
23.25
19.95
19.9
22.49
22.6
23.29
18.17
24.91
Operating Profit
4.14
7.36
5.23
6.1
4.24
11.41
1.43
2.43
3.56
6.06
6.05
1.44
6.37
OPM %
18.05%
28.43%
21.79%
26.73%
18.75%
32.92%
6.69%
10.88%
13.67%
21.14%
20.62%
7.34%
20.36%
Other Income
0.01
0.05
0.23
-0.05
0.07
1.02
0.27
0.79
1.84
0.48
1.33
0.36
0.94
Interest
0.02
0.03
0.02
0.05
0.02
0.03
0.01
0.02
0.02
0.05
0.01
0.04
0.02
Depreciation
0.83
0.85
0.87
0.89
0.9
0.91
0.91
0.92
0.9
0.94
0.93
0.93
0.96
PBT
3.3
6.53
4.57
5.11
3.39
11.49
0.78
2.28
4.48
5.55
6.44
0.83
6.33
Tax %
25.15%
25.27%
25.16%
27.2%
25.07%
25.15%
24.36%
27.63%
25.67%
25.59%
25.47%
-3.61%
25.59%
Net Profit
2.47
4.89
3.42
3.72
2.53
8.6
0.58
1.65
3.33
4.13
4.8
0.85
4.71
EPS (₹)
2.01
3.97
2.78
3.02
2.06
6.99
0.47
1.34
2.71
3.36
3.9
0.69
3.83
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
33
33
49
42
46
56
61
75
96
96
101
104
109
Expenses
26
26
40
34
38
46
45
59
78
73
81
87
89
Operating Profit
7
7
8
8
8
9
16
16
18
23
20
17
20
OPM %
22%
22%
17%
19%
18%
17%
26%
22%
19%
24%
19%
17%
18%
Other Income
0
0
0
0
0
0
2
0
0
0
2
4
3
Interest
4
4
2
2
2
1
1
0
0
0
0
0
0
Depreciation
2
3
3
3
3
3
3
3
3
3
4
4
4
PBT
1
1
3
3
3
6
15
13
15
20
18
17
19
Tax %
27%
58%
42%
42%
24%
21%
21%
27%
25%
26%
26%
24%
—
Net Profit
1
0
2
2
3
5
12
9
11
14
13
13
14
EPS (₹)
1.65
0.78
3.43
2.78
2.79
3.87
9.44
7.49
9.21
11.78
10.86
10.65
11.78
Div. Payout %
0%
0%
0%
0%
0%
32%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
3
3
3
3
4
6
6
12
12
12
12
12
Reserves
9
9
11
12
25
34
46
48
59
73
87
100
Borrowings
38
36
31
29
12
6
8
0
0
0
0
0
Other Liabilities
9
10
12
10
11
13
16
19
18
16
20
17
Total Liabilities
59
58
56
54
51
60
76
79
89
102
119
129
Fixed Assets
45
43
42
39
36
34
30
34
38
41
39
36
CWIP
0
0
0
0
0
1
5
0
0
0
0
1
Investments
0
0
0
0
0
0
0
0
0
0
25
27
Other Assets
13
15
14
15
15
25
42
44
50
60
55
65
Total Assets
59
58
56
54
51
60
76
79
89
102
119
129
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
9
7
9
4
2
8
12
8
13
20
16
16
Investing
0
0
-2
-1
0
-1
0
-3
-7
-6
-25
-2
Financing
-9
-5
-8
-4
-2
1
2
-10
0
0
0
0
Net Cash Flow
-1
1
-1
0
0
7
14
-5
6
14
-9
14
Free Cash Flow
9
6
7
4
2
6
12
4
6
14
15
14
CFO/EBITDA
127
91
116
59
34
90
98
66
97
108
106
125
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
83
81
61
75
67
81
75
90
65
52
60
42
Inventory Days
111
158
69
83
81
45
50
60
49
45
58
45
Days Payable
184
183
135
107
94
96
112
135
73
58
104
69
Cash Conversion Cycle
10
57
-5
51
55
30
13
14
40
40
15
19
Working Capital Days
61
66
-46
-26
13
39
24
61
50
40
39
31
ROCE %
10%
9%
12%
11%
12%
16%
25%
22%
23%
25%
18%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Par Drugs & Chemical insights

64 extracted metrics + investor summaries across FY15–FY27.

Shareholding Pattern

DIIs0.09%Promot.73.41%Others6.87%Public19.64%As ofSep 2026

Documents

1
Concall - Jun 2023 Jun 2023
2
Concall - Jun 2023 Jun 2023
3
Concall - Mar 2023 Mar 2023
4
Concall - Mar 2023 Mar 2023
5
Concall - Feb 2023 Feb 2023

Frequently Asked Questions about Par Drugs & Chemical

What does Par Drugs & Chemicals Ltd do?
Incorporated in 1982, Par Drugs & Chemicals Ltd manufactures APIs and Fine Chemicals[1]
Where is Par Drugs & Chemicals Ltd (PAR) listed?
Par Drugs & Chemicals Ltd trades as PAR on the NSE.
Which sector does Par Drugs & Chemicals Ltd belong to?
Par Drugs & Chemicals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Par Drugs & Chemicals Ltd?
Par Drugs & Chemicals Ltd has a market capitalisation of ₹141.45 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Par Drugs & Chemicals Ltd?
Par Drugs & Chemicals Ltd trades at a PE ratio of 9.76 as of 28 Oct 2026, on earnings per share of ₹11.78, against a book value of ₹91.01 per share.
What is the 52-week high and low of Par Drugs & Chemicals Ltd?
Over the last 52 weeks Par Drugs & Chemicals Ltd has traded between ₹78.05 and ₹180 as of 28 Oct 2026.
Does Par Drugs & Chemicals Ltd pay dividends?
Par Drugs & Chemicals Ltd has a dividend yield of 1.14%.
What is the Return on Equity (ROE) of Par Drugs & Chemicals Ltd?
Par Drugs & Chemicals Ltd reported a return on equity of 11.71%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 1982, Par Drugs & Chemicals Ltd manufactures APIs and Fine Chemicals[1]

Website pardrugs.com
Listed 2021-09-16
Face Value ₹ 10
Shares Outstanding 1,23,04,636

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/PAR.md for Par Drugs & Chemicals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month